2 October 2025 
VISCHER advised Blue Owl (NYSE: OWL) on all Swiss legal aspects of the financing transaction, including an up to USD 500 million term loan facility for Madrigal Pharmaceuticals (NASDAQ: MDGL). Blue Owl is a leading asset manager redefining alternatives and Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis.
The VISCHER team was led by Dr. Adrian Dörig and included Christian Schneiter and Dr. Balthasar Müller (all Financing) as well as Christoph Niederer (Tax).
Author: Christian Schneiter
Christoph Niederer
Attorney at Law, Swiss Certified Tax Expert
- Partner
- +41 58 211 34 37
- [email protected]